ArticleArteriosclerosis, thrombosis, and vascular biology2018
Association of Circulating Chemerin With Subclinical Parameters of Atherosclerosis: Results of a Population-Based Study.
Article in Arteriosclerosis, thrombosis, and vascular biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Trial
- Semaphorin 3 C is a Novel Adipokine Representing Exercise-Induced Improvements of Metabolism in Metabolically Healthy Obese Young Males.Scientific reports · 2020Trial
- Relationship of chemerin with nutritional status and appetitive traits in early childhood: a cross-sectional study.European journal of pediatrics · 2026Article
- Chemerin in the Spotlight: Revealing Its Multifaceted Role in Acute Myocardial Infarction.Biomedicines · 2024Review
- Adiponectin rs1501299 and chemerin rs17173608 gene polymorphism in children with type 1 diabetes mellitus: relation with macroangiopathy and peripheral artery disease.Journal of endocrinological investigation · 2024Article
- Targeting mitochondria by lipid-selenium conjugate drug results in malate/fumarate exhaustion and induces mitophagy-mediated necroptosis suppression.International journal of biological sciences · 2024Article
- Review of the Protective Mechanism of Curcumin on Cardiovascular Disease.Drug design, development and therapy · 2024Review
- Association of plasma chemerin with all-cause and disease-specific mortality - results from a population-based study.International journal of obesity (2005) · 2023Article
- The Role of Adipokines in Health and Disease.Biomedicines · 2023Review
- Molecular imaging of chemokine-like receptor 1 (CMKLR1) in experimental acute lung injury.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Role of Chemerin in Cardiovascular Diseases.Biomedicines · 2022Review
- Role of Chemerin/ChemR23 axis as an emerging therapeutic perspective on obesity-related vascular dysfunction.Journal of translational medicine · 2022Review
- Determinants of elevated chemerin as a novel biomarker of immunometabolism: data from a large population-based cohort.Endocrine connections · 2021Article
- Serum Chemerin Concentration Is Associated with Proinflammatory Status in Chronic Coronary Syndrome.Biomolecules · 2021Observational
- Adipokines and Arterial Stiffness in Obesity.Medicina (Kaunas, Lithuania) · 2021Review
- Article
- Chemerin enhances the adhesion and migration of human endothelial progenitor cells and increases lipid accumulation in mice with atherosclerosis.Lipids in health and disease · 2020Article
- Association of Adipocytokines With Carotid Intima Media Thickness and Arterial Stiffness in Obstructive Sleep Apnea Patients.Frontiers in endocrinology · 2020Article
- Updates on Approaches for Studying Atherosclerosis.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- Emerging Roles for Adipose Tissue in Cardiovascular Disease.Arteriosclerosis, thrombosis, and vascular biology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveChemerin has been shown to be associated with inflammation and metabolic syndrome, which are in turn leading risk factors for atherosclerosis. A few clinical studies have concentrated on the role of chemerin in atherosclerosis but revealed divergent findings. Therefore, we aimed to investigate the association of plasma chemerin levels with different subclinical measurements of atherosclerosis in a population-based sample. APPROACH AND
resultsLinear and logistic regression models with different atherosclerotic parameters as subclinical outcomes were applied to analyze data from 4003 subjects of the SHIP (Study of Health in Pomerania). After adjustment for metabolic and inflammatory parameters, these models revealed no association of chemerin with carotid intima-media thickness, carotid plaque, or carotid stenosis but a significant inverse association between chemerin and ankle-brachial index. In detail, logistic regression analysis showed that a 25-ng/mL increase in chemerin was associated with a 30% higher odd (95% confidence interval, 1.20-1.41) of having an ankle-brachial index value below the 25th age- and sex-specific quartile.
conclusionsOur analyses revealed a modest inverse association between chemerin and ankle-brachial index that remained consistent after adjustment for metabolic and inflammatory parameters. The association of chemerin with carotid intima-media thickness, carotid plaque, or carotid stenosis was not significant after adjustment for the same confounder set. The investigated subclinical atherosclerotic parameters are representative for the atherosclerotic burden of different arterial regions and different disease stages. Thus, our results might suggest that the value of chemerin as a marker of higher atherosclerotic risk differs depending on the affected arterial region and disease stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.